Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.26 AUD | -3.70% | -5.45% | +8.33% |
Mar. 15 | Nova Eye Medical Completes Retail Entitlement Offer | MT |
Feb. 22 | Nova Eye Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2024 * | 22M 14.57M | Sales 2025 * | 30.7M 20.32M | Capitalization | 59.49M 39.38M |
---|---|---|---|---|---|
Net income 2024 * | -8M -5.3M | Net income 2025 * | -1M -662K | EV / Sales 2024 * | 2.39 x |
Net cash position 2024 * | 7M 4.63M | Net cash position 2025 * | 4.4M 2.91M | EV / Sales 2025 * | 1.79 x |
P/E ratio 2024 * |
-6.18
x | P/E ratio 2025 * |
-21.8
x | Employees | 301 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.39% |
Latest transcript on Nova Eye Medical Limited
1 day | -3.70% | ||
1 week | -5.45% | ||
Current month | -7.14% | ||
1 month | +8.33% | ||
3 months | -7.14% | ||
6 months | +52.94% | ||
Current year | +8.33% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Spurling
CEO | Chief Executive Officer | - | 11-03-30 |
David Lubeck
CTO | Chief Tech/Sci/R&D Officer | - | 18-10-17 |
Mark Flynn
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Victor Previn
FOU | Founder | 65 | 84-12-31 |
Thomas Spurling
CEO | Chief Executive Officer | - | 11-03-30 |
Rahmon Coupe
BRD | Director/Board Member | 60 | 13-05-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-05 | 0.26 | -3.70% | 305 737 |
24-05-03 | 0.27 | -1.82% | 410,605 |
24-05-02 | 0.275 | +3.77% | 280,937 |
24-05-01 | 0.265 | -5.36% | 540,773 |
24-04-30 | 0.28 | +1.82% | 589,541 |
Delayed Quote Australian S.E., May 05, 2024 at 11:41 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.33% | 40.85M | |
+8.46% | 218B | |
+7.62% | 184B | |
+13.29% | 135B | |
+0.04% | 62.38B | |
+11.92% | 51.37B | |
+4.81% | 50.9B | |
+1.17% | 40.87B | |
+2.35% | 36.28B | |
+26.28% | 31.88B |
- Stock Market
- Equities
- EYE Stock